Events

Retiro De Equipo (Recall) de therascreen PyroMark Gold Q24 Reagents and Pyro Buffers. An in vitro diagnostic medical device (IVD)

Según Department of Health, Therapeutic Goods Administration, este evento ( retiro de equipo (recall) ) involucró a un dispositivo médico en Australia que fue producido por Qiagen Pty Ltd.

¿Qué es esto?

Una corrección al equipo o acción de retiro tomada por el fabricante para abordar un problema con un dispositivo médico. Los retiros (recalls) ocurren cuando un dispositivo médico está defectuoso, cuando puede poner en riesgo la salud, o cuando simultáneamente está defectuoso y puede poner en riesgo la salud.

Más información acerca de la data acá
  • Tipo de evento
    Recall
  • ID del evento
    RC-2018-RN-00069-1
  • Clase de Riesgo del Evento
    Class II
  • Fecha de inicio del evento
    2018-01-22
  • País del evento
    Australia
  • Fuente del evento
    DHTGA
  • URL de la fuente del evento
    https://apps.tga.gov.au/Prod/sara/arn-detail.aspx?k=RC-2018-RN-00069-1
  • Notas / Alertas
    Australian data is current through July 2018. All of the data comes from the Australian Therapeutic Goods Administration, except for the categories Manufacturer Parent Company and Product Classification.
    The Parent Company and the Product Classification were added by ICIJ.
    The parent company information is based on 2017 public records. The device classification information comes from FDA’s Product Classification by Review Panel, based on matches of recall data from the U.S. and Australia.
  • Notas adicionales en la data
  • Causa
    Qiagen have identified an increased number of cases with altered ratios in the pyrogram peak patterns for therascreen pyrosequencing assays. use of the affected lots is associated with an elevated invalidity and re-testing rate.In addition, use of the affected lots also creates an elevated risk of a59t false positive results for the pyrosequencing analysis of nras codon 59 with the therascreen ras extension pyro kit (ref 971590).In pyrosequencing runs performed with the affected material, the ratio of the peak height for datp peaks in pyrograms is artificially increased while in parallel the peak height for dgtp may be decreased. this may result in an altered ratio of peak heights and consequently leads to an incorrect determination of allele mutation frequencies.
  • Acción
    Qiagen is advising users to discontinue use of the affected lots and contact Qiagen for replacement lots. Please ensure the corresponding assay Plug-in reports for automated result interpretation are used. If users have used the affected lots, it is strongly recommend a review of the corresponding results.

Device

therascreen PyroMark Gold Q24 Reagents and Pyro Buffers. An in vitro diagnostic medical device (IVD)
  • Modelo / Serial
    therascreen PyroMark Gold Q24 Reagents and Pyro Buffers. An in vitro diagnostic medical device (IVD)PyroMark Gold Q24 ReagentsMaterial Number: 1055272Lot Numbers: 157010641, 157025615, 157027017, 157030977therascreen Pyro Buffers and ReagentMaterial Number: 1063948Lot Numbers: 157013230, 157013013, 157027507, 157028499, 157028495, 157030047, 157035803, 157033230ARTG Number: 226453 (Qiagen Pty Ltd - Acquired genetic alteration IVDs)
  • Manufacturer
    Qiagen Pty Ltd

Manufacturer

Qiagen Pty Ltd